Interventions to increase HPV vaccine uptake "high-value" resource use
- PDF / 167,133 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 29 Downloads / 223 Views
1
Interventions to increase HPV vaccine uptake "high-value" resource use Interventions to increase human papillomavirus (HPV) vaccine uptake are cost effective from a US state perspective, report researchers from the US. The researchers used a dynamic model of HPV infection, transmission and progression to cancer in a heterosexual US population to evaluate the costs and benefits of three evidence-based interventions to increase HPV vaccine uptake, assuming a one-time year-long implementation: centralised reminder and recall; school-located vaccination; and quality improvement (QI) visits. State-wide implementation of any of the three interventions was cost effective, compared with no intervention. Each of the interventions increased the number of adolescents initiating HPV vaccine, ranging from 3733 to 18 721 additional HPV vaccine initiators for QI visits and school-located vaccinations, respectively. Over a 50-year time horizon, the number of cancer cases averted ranged from 44 to 212, respectively, representing 3000–14 000 cancers averted if scaled up to the full US population. Total intervention costs for the state were estimated at $US64 855 for QI visits, $984 270 for reminder and recall, and $3 038 752 for school-located vaccination (year 2018 values). Incremental cost-effectiveness ratios were well below the $50 000-per-QALY threshold, ranging from $1538 to $14 871 per QALY gained for QI visits and school-located vaccination, respectively. School-located vaccination had the largest benefit and was cost effective relative to alternatives. "These interventions are a high-value use of state prevention resources," conclude the researchers. Spencer JC, et al. Cost-effectiveness of Interventions to Increase HPV Vaccine Uptake. Pediatrics : 16 Nov 2020. Available from: URL: https://doi.org/10.1542/ peds.2020-0395
1173-5503/20/0867-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
803517429
PharmacoEconomics & Outcomes News 28 Nov 2020 No. 867
Data Loading...